Small-Cell Lung Cancer – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Small-Cell Lung Cancer – Pipeline Review, H2 2019’, provides an overview of the Small-Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer

– The report reviews pipeline therapeutics for Small-Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Small-Cell Lung Cancer therapeutics and enlists all their major and minor projects

– The report assesses Small-Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Advanced Accelerator Applications SA

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Akeso Biopharma Inc

Allogene Therapeutics Inc

Altor Bioscience LLC

Amgen Inc

Andarix Pharmaceuticals Inc

Apollomics Inc

Aposense Ltd

Aprea Therapeutics AB

Ascenta Therapeutics Inc

Ascentage Pharma Group International

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Auransa Inc

Autolus Therapeutics Plc

Bavarian Nordic A/S

BeiGene Ltd

Beta Pharma Inc

BeyondSpring Inc

Biogenera SpA

BioLineRx Ltd

BioNTech SE

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Carrick Therapeutics UK Ltd

Celldex Therapeutics Inc

Checkpoint Therapeutics Inc

Chiome Bioscience Inc

Chipscreen Biosciences Ltd

Coherent Biopharma

Cotinga Pharmaceuticals Inc

CSPC Pharmaceutical Group Ltd

CStone Pharmaceuticals Co Ltd

Cumberland Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Eli Lilly and Co

EpicentRx Inc

Esanex Inc

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

G1 Therapeutics Inc

GlaxoSmithKline Plc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

Harpoon Therapeutics Inc

Hillstream BioPharma Inc

Horizon Therapeutics PLC

Hutchison MediPharma Ltd

ImmunityBio Inc

Immunocore Ltd

Immunomedics Inc

ImmunSYS Inc

Incyte Corp

Innovent Biologics Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Lee’s Pharmaceutical Holdings Ltd

Lixte Biotechnology Holdings Inc

MabVax Therapeutics Holdings Inc

Merck & Co Inc

Merck KGaA

Moderna Therapeutics Inc

Mologen AG

MultiVir Inc

Mundipharma EDO GmbH

Nektar Therapeutics

NewBio Therapeutics Inc

NewLink Genetics Corp

Ningbo Wenda Pharma

Nippon Kayaku Co Ltd

Northlake International LLC

Novartis AG

NOX Pharmaceuticals Inc

OncoFusion Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oryzon Genomics SA

Oxford BioTherapeutics Ltd

Pfizer Inc

Phanes Therapeutics Inc

Pharma Mar SA

Plexxikon Inc

Plus Therapeutics Inc

Rafael Pharmaceuticals Inc

Recombio SL

Rexahn Pharmaceuticals Inc

Rgenix Inc

SciTech Development LLC

Seattle Genetics Inc

SELLAS Life Sciences Group Inc

Seneca Therapeutics Inc

Shanghai Henlius Biotech Inc

Shanghai Junshi Bioscience Co Ltd

Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd

Sierra Oncology Inc

Sorrento Therapeutics Inc

Sound Biologics

Starpharma Holdings Ltd

Sun Pharma Advanced Research Company Ltd

Syros Pharmaceuticals Inc

Tactical Therapeutics Inc

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Targovax ASA

Tarveda Therapeutics Inc

Telomium SAS

Tmunity Therapeutics Inc

Trillium Therapeutics Inc

Trovagene Inc

United Therapeutics Corp

Woomera Therapeutics Inc

Xbrane Biopharma AB

Xcovery Holding Company LLC

Xencor Inc

Y-Biologics

Zensun (Shanghai) Sci & Tech Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Small-Cell Lung Cancer Overview 8

Small-Cell Lung Cancer Therapeutics Development 9

Small-Cell Lung Cancer Therapeutics Assessment 26

Small-Cell Lung Cancer Companies Involved in Therapeutics Development 40

Small-Cell Lung Cancer Drug Profiles 76

Small-Cell Lung Cancer Dormant Projects 779

Small-Cell Lung Cancer Discontinued Products 785

Small-Cell Lung Cancer Product Development Milestones 787

Appendix 795

List of Tables

List of Tables

Number of Products under Development for Small-Cell Lung Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Small-Cell Lung Cancer – Pipeline by AbbVie Inc, H2 2019

List of Figures

List of Figures

Number of Products under Development for Small-Cell Lung Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports